<DOC>
	<DOCNO>NCT01388387</DOCNO>
	<brief_summary>The choice immunosuppressant hepatic transplant difficult increase number drug available . Pharmacokinetic , pharmacodynamic pharmacogenetic information help choose best treatment best dose patient . The genetic polymorphism enzyme metabolize treatment affect efficacy safety . Concerning tacrolimus , CYP3A5 activity major determinant dose need reach target concentration . This study aim evaluate impact donor recipient CYP3A5 genetic polymorphism tacrolimus exposure patient hepatic transplant .</brief_summary>
	<brief_title>Pharmacogenetic Study Tacrolimus Hepatic Transplant ( CYPTAC ' H )</brief_title>
	<detailed_description>Pharmacogenetics recent tool could help choose best immunosuppressive therapy patient hepatic transplant . Indeed , CYP3A5 gene many polymorphisms one , g.6986 A &gt; G , major determinant variability expression protein . The allele *1 ( g6986A ) lead normal protein expression allele *3 ( g.6986G ) cause lack protein expression , different combination induce great variability tacrolimus concentration . As cytochromes present liver intestine , hepatic transplant , tacrolimus exposure result recipient ( enterocytes ) donor ( liver ) enzymes . Recent study demonstrate significant role genotype recipient dose/concentration relationship dose need reach target concentration . However , study insufficient analyze precisely impact polymorphism include enough patient . The purpose investigator study evaluate impact donor recipient CYP3A5 genetic polymorphism tacrolimus exposure patient hepatic transplant first administration tacrolimus 7 day post transplantation , dose adapt avoid high blood level limit serious adverse reaction .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Adults ( &gt; 18 year ) Caucasian origin , hepatic transplant , go treat tacrolimus , give free , wellinformed write consent . Noninclusion Criteria : Participation another protocol incompatible study , HIV patient antiretroviral treatment , Patients legal guardianship deprive freedom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pharmacogenetics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>genetic polymorphism</keyword>
	<keyword>CYP3A5</keyword>
	<keyword>liver transplantation</keyword>
</DOC>